Table of Contents

1 Study Coverage

• 1.1 Endometriosis Drugs Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Endometriosis Drugs Market Size Growth Rate by Product
  • 1.4.2 Hormonal Therapy
  • 1.4.3 Add-back Medication
  • 1.4.4 Progestogens
  • 1.4.5 Chinese Herbs
• 1.5 Market by End User
  • 1.5.1 Global Endometriosis Drugs Market Size Growth Rate by End User
  • 1.5.2 Hospitals
  • 1.5.3 Clinics
  • 1.5.4 Research Institutes
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Endometriosis Drugs Market Size
  • 2.1.1 Global Endometriosis Drugs Revenue 2014-2025
  • 2.1.2 Global Endometriosis Drugs Sales 2014-2025
• 2.2 Endometriosis Drugs Growth Rate by Regions
  • 2.2.1 Global Endometriosis Drugs Sales by Regions
  • 2.2.2 Global Endometriosis Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Endometriosis Drugs Sales by Manufacturers
  • 3.1.1 Endometriosis Drugs Sales by Manufacturers
  • 3.1.2 Endometriosis Drugs Sales Market Share by Manufacturers
  • 3.1.3 Global Endometriosis Drugs Market Concentration Ratio (CR5 and HHI)
• 3.2 Endometriosis Drugs Revenue by Manufacturers
  • 3.2.1 Endometriosis Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Endometriosis Drugs Revenue Share by Manufacturers (2014-2019)
• 3.3 Endometriosis Drugs Price by Manufacturers
• 3.4 Endometriosis Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Endometriosis Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Endometriosis Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Endometriosis Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Endometriosis Drugs Sales by Product
• 4.2 Global Endometriosis Drugs Revenue by Product
• 4.3 Endometriosis Drugs Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Endometriosis Drugs Breakdown Data by End User

6 North America

• 6.1 North America Endometriosis Drugs by Countries
  • 6.1.1 North America Endometriosis Drugs Sales by Countries
  • 6.1.2 North America Endometriosis Drugs Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Endometriosis Drugs by Product
• 6.3 North America Endometriosis Drugs by End User

7 Europe

• 7.1 Europe Endometriosis Drugs by Countries
  • 7.1.1 Europe Endometriosis Drugs Sales by Countries
  • 7.1.2 Europe Endometriosis Drugs Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Endometriosis Drugs by Product
• 7.3 Europe Endometriosis Drugs by End User

8 Asia Pacific

• 8.1 Asia Pacific Endometriosis Drugs by Countries
  • 8.1.1 Asia Pacific Endometriosis Drugs Sales by Countries
  • 8.1.2 Asia Pacific Endometriosis Drugs Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Endometriosis Drugs by Product
• 8.3 Asia Pacific Endometriosis Drugs by End User

9 Central & South America

• 9.1 Central & South America Endometriosis Drugs by Countries
  • 9.1.1 Central & South America Endometriosis Drugs Sales by Countries
  • 9.1.2 Central & South America Endometriosis Drugs Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Endometriosis Drugs by Product
• 9.3 Central & South America Endometriosis Drugs by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Endometriosis Drugs by Countries
  • 10.1.1 Middle East and Africa Endometriosis Drugs Sales by Countries
  • 10.1.2 Middle East and Africa Endometriosis Drugs Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Endometriosis Drugs by Product
• 10.3 Middle East and Africa Endometriosis Drugs by End User

11 Company Profiles

• 11.1 AbbVie
  • 11.1.1 AbbVie Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 AbbVie Endometriosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 AbbVie Endometriosis Drugs Products Offered
  • 11.1.5 AbbVie Recent Development
• 11.2 Astellas Pharma
  • 11.2.1 Astellas Pharma Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Astellas Pharma Endometriosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Astellas Pharma Endometriosis Drugs Products Offered
  • 11.2.5 Astellas Pharma Recent Development
• 11.3 AstraZeneca
  • 11.3.1 AstraZeneca Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 AstraZeneca Endometriosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 AstraZeneca Endometriosis Drugs Products Offered
  • 11.3.5 AstraZeneca Recent Development
• 11.4 Debiopharm Group
  • 11.4.1 Debiopharm Group Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Debiopharm Group Endometriosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Debiopharm Group Endometriosis Drugs Products Offered
  • 11.4.5 Debiopharm Group Recent Development
• 11.5 Evotec AG
  • 11.5.1 Evotec AG Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Evotec AG Endometriosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Evotec AG Endometriosis Drugs Products Offered
  • 11.5.5 Evotec AG Recent Development
• 11.6 Kissei Pharmaceutical
  • 11.6.1 Kissei Pharmaceutical Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Kissei Pharmaceutical Endometriosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Kissei Pharmaceutical Endometriosis Drugs Products Offered
  • 11.6.5 Kissei Pharmaceutical Recent Development
• 11.7 Neurocrine Biosciences
  • 11.7.1 Neurocrine Biosciences Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Neurocrine Biosciences Endometriosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Neurocrine Biosciences Endometriosis Drugs Products Offered
  • 11.7.5 Neurocrine Biosciences Recent Development
• 11.8 ObsEva
  • 11.8.1 ObsEva Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 ObsEva Endometriosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 ObsEva Endometriosis Drugs Products Offered
  • 11.8.5 ObsEva Recent Development
• 11.9 Pfizer
  • 11.9.1 Pfizer Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Pfizer Endometriosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Pfizer Endometriosis Drugs Products Offered
  • 11.9.5 Pfizer Recent Development
• 11.10 Repros Therapeutics
  • 11.10.1 Repros Therapeutics Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Repros Therapeutics Endometriosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Repros Therapeutics Endometriosis Drugs Products Offered
  • 11.10.5 Repros Therapeutics Recent Development
• 11.11 Roivant Sciences GmbH
• 11.12 Takeda Pharmaceutical Company Limited
• 11.13 ValiRx

12 Future Forecast

• 12.1 Endometriosis Drugs Market Forecast by Regions
  • 12.1.1 Global Endometriosis Drugs Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Endometriosis Drugs Revenue Forecast by Regions 2019-2025
• 12.2 Endometriosis Drugs Market Forecast by Product
  • 12.2.1 Global Endometriosis Drugs Sales Forecast by Product 2019-2025
  • 12.2.2 Global Endometriosis Drugs Revenue Forecast by Product 2019-2025
• 12.3 Endometriosis Drugs Market Forecast by End User
• 12.4 North America Endometriosis Drugs Forecast
• 12.5 Europe Endometriosis Drugs Forecast
• 12.6 Asia Pacific Endometriosis Drugs Forecast
• 12.7 Central & South America Endometriosis Drugs Forecast
• 12.8 Middle East and Africa Endometriosis Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Endometriosis Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Endometriosis affects an estimated 1 in 10 women in the reproductive age group of 15-49 years.
Among these therapies, Elagolix, a first-in-class GnRH receptor antagonist, is closest to market.
The global Endometriosis Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Endometriosis Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Endometriosis Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Endometriosis Drugs in these regions.
This research report categorizes the global Endometriosis Drugs market by top players/brands, region, type and end user. This report also studies the global Endometriosis Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
AbbVie
Astellas Pharma
AstraZeneca
Debiopharm Group
Evotec AG
Kissei Pharmaceutical
Neurocrine Biosciences
ObsEva
Pfizer
Repros Therapeutics
Roivant Sciences GmbH
Takeda Pharmaceutical Company Limited
ValiRx

Market size by Product
Hormonal Therapy
Add-back Medication
Progestogens
Chinese Herbs
Market size by End User
Hospitals
Clinics
Research Institutes

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Endometriosis Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Endometriosis Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Endometriosis Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Endometriosis Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Endometriosis Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Endometriosis Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.